High-density lipoproteins and myocardial necrosis in patients with acute myocardial infarction and ST segment elevation

Fabregat-Andrés, Óscar; Ferrando-Beltrán, Mónica; Lucas-Inarejos, Elena; Estornell-Erill, Jordi; Fácila, Lorenzo; Ridocci-Soriano, Francisco

doi:10.1016/j.rceng.2012.12.003

Cited by 3 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All these studies were consistent with the evidence that increased HDL-C plasma levels are associated with a reduced risk of CVD and MI, due to different mechanisms such as reverse cholesterol transportation and inhibition of in ammatory factor expression accomplished by this lipoprotein (49,50). Additionally, we observed a positive association between high HDL-C levels and ST-segment elevation as a minor ischemic abnormality, which was contrary with previous studies that had announced low HDL-C as a risk factor for ST-elevation myocardial infarction (STEMI) (51,52). In a study conducted by Kumar et al, on 3224 participants with the mean age of 72, no signi cant association was observed between HDL-C and NSSTTAs in older Americans (42); also, in a heterogeneous population-based study from the U.S., there was no signi cant relationship between low HDL-C and ECG abnormalities (34); in addition, a Korean study declared that low HDL-C was not a signi cant risk factor for ischemic ECG presentations in female (32).…”

Section: Discussioncontrasting

confidence: 99%

Association of Metabolic Syndrome and Ischemic Changes in ECG: Result from a Population-Based Study

Soflaei,

Varasteh,

Pourali

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Metabolic syndrome (MetS) is a set of metabolic impairments that are all risk factors for cardiovascular diseases (CVDs). To distinguish and anticipate the CVD risk, an electrocardiogram (ECG) can be utilized. While the exact association between MetS components and ECG abnormalities isn’t well established yet, we designed this study to verify the association between MetS components and ischemic ECG presentations. Methods This cross-sectional study was conducted on individuals aged 35–65 years as part of the population-based Mashhad stroke and heart atherosclerotic disorder (MASHAD) study. International Diabetes Federation (IDF) criteria were utilized to categorize the participants into two groups: those with and without MetS. ECGs were coded using the Minnesota coding system. The association between each MetS component and every single ischemic ECG presentation was analysed separately. Results Among the 9035 available ECG data, the general prevalence of ischemic ECG presentation was significantly higher in those with MetS than in those without (p < 0.05), except for minor ischemia (P = 0.787). Multiple logistic regression analysis showed that MetS was independently associated with major ischemia presentation in ECG (OR = 1.254, 95% Cl: 1.103–1.425, P < 0.001), but there wasn’t any association found with minor ischemia, after adjustment for age, sex, smoking, CVD family history, and physical activity level. Among Mets components, triglycerides, fasting blood glucose, waist circumference, and systolic and diastolic blood pressures had significantly positive associations with ischemic ECG presentations in the case of any association. Elevated high-density lipoprotein cholesterol level had negative associations with ischemic ECG presentations, while it had a significant positive association only with ST-segment elevation (OR = 1.021, 95% Cl: 1.011–1.031, P < 0.001). Conclusions MetS and its components showed an association with ischemic ECG presentations, but these associations were diverse, based on each MetS component and ischemic ECG abnormality.

show abstract

Section: Discussioncontrasting

confidence: 99%

Association of Metabolic Syndrome and Ischemic Changes in ECG: Result from a Population-Based Study

Soflaei,

Varasteh,

Pourali

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…However, there have been controversies about the impact of HDL on clinical outcome in non-ST-segment-elevation myocardial infarction (NSTEMI) patients [4][5][6], while there is lack of data in STsegment-elevation myocardial infarction (STEMI) patients [7]. Considering different clinical features of STEMI and NSTEMI [8], it might be important to compare the impact of HDL on clinical outcome in both populations.…”

Section: Introductionmentioning

confidence: 99%

Impact of low level of high-density lipoprotein-cholesterol sampled in overnight fasting state on the clinical outcomes in patients with acute myocardial infarction (difference between ST-segment and non-ST-segment-elevation myocardial infarction)

Jeong

Kim

et al. 2015

Journal of Cardiology

View full text Add to dashboard Cite

show abstract

“…Whether low HDL-C levels predict poor cardiovascular outcomes in acute myocardial infarction (AMI) patients has been a matter of controversy [5,6]. In this regard, vascular effects of HDL-C can be highly heterogeneous in various clinical conditions [7], and its antiinflammatory function may be impaired in patients with coronary artery disease (CAD) [8].…”

Section: Introductionmentioning

confidence: 99%

Predictive and protective role of high-density lipoprotein cholesterol in acute myocardial infarction

et al. 2013

View full text Add to dashboard Cite

show abstract

High-density lipoproteins and myocardial necrosis in patients with acute myocardial infarction and ST segment elevation

Cited by 3 publications

References 12 publications

Association of Metabolic Syndrome and Ischemic Changes in ECG: Result from a Population-Based Study

Association of Metabolic Syndrome and Ischemic Changes in ECG: Result from a Population-Based Study

Impact of low level of high-density lipoprotein-cholesterol sampled in overnight fasting state on the clinical outcomes in patients with acute myocardial infarction (difference between ST-segment and non-ST-segment-elevation myocardial infarction)

Predictive and protective role of high-density lipoprotein cholesterol in acute myocardial infarction

Contact Info

Product

Resources

About